Skip to main content
SpringerLink
Log in

Psychopharmakoökonomie

  • Chapter
Handbuch der Psychopharmakotherapie

  • 2558 Accesses

Auszug

Die finanziellen Ressourcen, die dem Gesundheitswesen zur Verfügung stehen, sind und werden immer begrenzt sein. Diese Begrenzung zwingt dazu, auch bei medizinischen Entscheidung ökonomische Überlegungen zur Unterstützung eines rationalen und rationellen Mitteleinsatzes im Gesundheitswesen einzubeziehen. Gesundheitsökonomische Evaluation ist nur interdisziplinär denkbar: Auf der medizinischen Seite muss die generelle klinische (efficacy) und praktische Wirksamkeit (effectiveness) von medizinischen Behandlungen erforscht werden; dann erst kann die Effizienz der Behandlung (efficiency, definiert als maximaler Nettonutzen bei gegebenem Ressourceneinsatz oder minimaler Ressourceneinsatz bei gegebenem Nettonutzen) bestimmt werden (Health Council of the Netherlands 2001).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Andllin-Sobocki P (2004) Economic evidence in addiction: a review. Eur J Health Econ 5, (Suppl 1): S5–S12

    Article  Google Scholar 

  • Bagnall AM et al (2003) A system atic review of atypical drugs in schizophrenia. Health Technol Assess 7 (13)

    Google Scholar 

  • Baker CB et al (2003) Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 183: 498–506

    Article  PubMed  Google Scholar 

  • Barbieri M et al (2005) Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: Lessons for inferring generalizability. Value Health 8: 10–23

    Article  PubMed  Google Scholar 

  • Barbui C et al (2003) Economic evaluation of antidepressive agents: a systematic critique of experimental and observational studies. J Clinl Psychopharmacol 23: 145–154

    Article  Google Scholar 

  • Barbui C et al (2005) Head-to-head comparison of the costs of atypical antipsychotics: a systematic review. CNS Drugs 19: 935–950

    Article  PubMed  Google Scholar 

  • Barnett PG, Hui, SS (2000) The cost-effectiveness of methadone maintenance. Mt Sinal J Med 67: 365–374

    CAS  Google Scholar 

  • Barrett B et al (2005) Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord 84: 1–13

    Article  PubMed  Google Scholar 

  • Bergmann E, Horch K (2002) Kosten alkoholassozierter Krankheiten. Schätzungen für Deutschland. Robert Koch-Institut, Berlin

    Google Scholar 

  • Bridle C et al (2004) A rapid and systematic review of the clinicals and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess 8 (19)

    Google Scholar 

  • Dijkgraaf MGW et al (2005) Cost utillity analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ 330: 1297–1302

    Article  PubMed  Google Scholar 

  • Fachverband Sucht (2006) Verbrauch Missbrauch, Abhängigkeit — Zahlen und Fakten. Internet; URL: http://www.sucht.de/fakten/medikamente. pdf 15.05.2006

    Google Scholar 

  • Fergusson D et al (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 330: 396–402

    Article  PubMed  CAS  Google Scholar 

  • Fillit H, Hill J (2005) Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother 3: 39–49

    Article  PubMed  Google Scholar 

  • FranÇois C et al (2004) Cost effectiveness of memantine in moderately severe to severe Alzheimer’s disease: a Markov model in Finland. Clin Drug Invest 24: 373–384

    Article  Google Scholar 

  • Frank E et al (2005) Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 62: 996–1004

    Article  PubMed  Google Scholar 

  • Ganguly R et al (2003) Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. Schizophrs Res 63: 111–119

    Article  Google Scholar 

  • Geddes JR, Cipriani A (2004) Selective serotonin reuptake inhibitors (Editorial). BMJ 329: 809–810

    Article  PubMed  Google Scholar 

  • Green C et al (2005) Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderate severe Alzheimer’s disease. Pharmacoeconomics 23: 1271–1282

    Article  PubMed  CAS  Google Scholar 

  • Greenhalgh J et al (2005) Cinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 9 (9)

    Google Scholar 

  • Greiner W (1999) Ökonomische Evaluation von Gesundheitsleistungen. Baden-Baden, Nomos

    Google Scholar 

  • Hamann J et al (2003) Are the second generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 36: 18–26

    Article  PubMed  CAS  Google Scholar 

  • Han D, Wang ECY (2005) Remission from depression. A review of venlafaxine clinical and economic evidence. Pharmacoeconomics 23: 567–581

    Article  PubMed  CAS  Google Scholar 

  • Haycox A (2005) Pharmacoeconomics of long-acting risperidone: resutls and validity of cost-effectiveness models. Pharmacoeconomics 23 (Suppl 1): 3–16

    Article  PubMed  CAS  Google Scholar 

  • Health Council of the Netherlands (2001) The efficiency of long-term psychotherapy. The Hague: Health Council of the Netherlands publication no. 2001/08E

    Google Scholar 

  • Health Evidence Network (authors: Möller H-J, Henkel V) (2005) What are the most effective diagnostic and therapeutic strategies for the management of depression in specialist care? WHO Regional Office for Europe, Copenhagen

    Google Scholar 

  • Hellewell JSE (2006) A review of the evidence for the use of antipsychotics in the maintenances treatment of bipolar disorder. J Psychopharmacol 20 (Suppl): 39–45

    Article  PubMed  CAS  Google Scholar 

  • Heres S et al (2006) Why Olanzapine beats Risperidone, Risperidone beats Quetiapine, and Quetiapine beats Olanzapine: An exploratory analysis of heat-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163: 185–194

    Article  PubMed  Google Scholar 

  • Holder HD (1998) Cost benefits of substance abuse treatment: an overview of results from alcohol and drug abuse. J Ment Health Pol Econ 1: 23–29

    Article  Google Scholar 

  • Holder HD et al (2000) Alcoholism treatment and medical care costs from project MATCH. Addiction 95:999–1013

    Article  PubMed  CAS  Google Scholar 

  • Holm KJ et al (2000) Mitrazapine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics 17:515–534

    Article  PubMed  CAS  Google Scholar 

  • Humphreys K et al (2004) Self-help organizations for alcohol and drug problems: Toward evidence-based practice and policy. J Subst Abuse Treat 26: 151–158

    Article  PubMed  Google Scholar 

  • Jacobl F et al (2004) Prevalences, co-morbidity and correlates of mental disorders in the general population: results from the German Health interview and Examination Survey (GHS). Psychol Med 34: 597–611

    Article  Google Scholar 

  • Jahrbuch Sucht 2004 (2003) Herausgegeben von der Deutschen Hauptstelle für Suchtfragen e.V., Geesthacht

    Google Scholar 

  • Jönsson B et al (2002) Cost of dementia: a review. In: Maj M, Sartorius N (Hrsg), Dementia, 2. Aufl., Chichester, Wiley, S 341–369. Commentaries: S 370–387

    Google Scholar 

  • John U, Hanke M (2002) Alcohol-attributable mortality in a high per capita consumption country-Germany. Alcohol Alcohol 37: 581–585

    PubMed  Google Scholar 

  • Jones RW et al (2004) Cost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 21: 607–620

    Article  PubMed  CAS  Google Scholar 

  • Knapp M (2000) Schizophrenia costs and treatment cost-effectiveness, in: Acta Psychiatr Scand 102 (Suppl 407): 15–18

    Article  Google Scholar 

  • Knapp M et al (2004) Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 184: 509–516

    Article  PubMed  Google Scholar 

  • Kulp W et al (2005) Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur J Health Econ 6: 317–321

    Article  PubMed  Google Scholar 

  • Laux G et al (2005) Costs and effects of long-acting risperidon compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 23 (Suppl 1): 49–61

    Article  PubMed  CAS  Google Scholar 

  • Lenroot R et al (2003) Integrated treatment of schizophrenia. Psychiatr Serv 54: 1499–1507

    Article  PubMed  Google Scholar 

  • Ludbrook A et al (2001) Effective and cost-effective measures to reduce alcohol misuse in Scotland: a literature review, Edinburgh: Scottish Executive Health Department

    Google Scholar 

  • Magnus A et al (2005) Assessing cost-effectiveness of drug interventions for schizophrenia, in: Aust N Z J Psychiatry 39: 44–54

    Article  PubMed  Google Scholar 

  • Martikainen J et al (2004) Potential cost-effectiveness of a family-based program in mild Alzheimer’s disease patients. Eur J Health Econ 5: 136–142

    PubMed  Google Scholar 

  • McCrone P et al (2004) Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 185: 55–61

    Article  PubMed  Google Scholar 

  • Mortimer D, Segal L (2005) Economic evaluation of interventions for problem drinking and alcohol dependence. Alcohol Alcohol 40: 549–555

    PubMed  Google Scholar 

  • Mortimer D, Segal L (2006) Economic evaluation of interventions for problem drinking and alcohol dependence: do within-familly external effects make a difference? Alcohol Alcohol 41: 92–98

    PubMed  Google Scholar 

  • O’Farrell TJ, Fals-Stewart W (2000) Behavioral couples therapy for alcoholism and drug abuse. J Subst Abuse Treat 18: 51–54

    Article  Google Scholar 

  • Parker G et al (2003) Cognitive behavior therapy for depression? Choose horses for courses. Am J Psychiatry 160: 825–834

    Article  PubMed  Google Scholar 

  • Perlis RH et al (2006) Predictors of recurrence in bipolar disorder: primary outcomes from the Syst ematic Treatment Enhancement Program for bipolar disorder (STEP-BD). Am J Psychiatry 163: 217–224

    Article  PubMed  Google Scholar 

  • Pirraglia PA et al (2004) Cost-utillity analysis studies of depression management: a systematic review. Am J Psychiatry 161: 2155–2162

    Article  PubMed  Google Scholar 

  • Plosker GL, Lyseng-Williamson KA (2005) Memantine. A pharmacoeconomic review of its use in moderate-to-severe Alzheimer’s disease. Pharmacoeconomics 23: 193–206

    Article  PubMed  Google Scholar 

  • Powers RH et al (2002) Psychotherapy and pharmacotherapy in depression. J Ment Health Pol Econ 5: 153–161

    Google Scholar 

  • Revicki DA et al (2003) Divalproex sodium versus olanzapine in the treatment of bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 64: 288–294

    Article  PubMed  CAS  Google Scholar 

  • Rössler W et al (2005) Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15: 399–409

    Article  PubMed  CAS  Google Scholar 

  • Rychlik R et al (2003) Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients. Eur Addict Res 9: 59–64

    Article  PubMed  CAS  Google Scholar 

  • Salize HJ, Rössler W (1996) How expensive is the comprehensive health care of schizophrenia patients living in the community? A cost evaluation from a German catchment area. Br J Psychiatry 169: 42–48

    Article  PubMed  CAS  Google Scholar 

  • Salkever D et al (2006) Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients: estimates from a prospective na turalistic study. Pharmacoeconomics 24: 123–139

    Article  PubMed  Google Scholar 

  • Schädlich PK, Brecht JG (1998) The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Pharmacoeconomics 13: 719–730

    Article  PubMed  Google Scholar 

  • Scott J et al (2003) Use of cognitive therapy for relapse prevention in chronic depression. Br J Psychiatry 182: 221–227

    Article  PubMed  Google Scholar 

  • Scott J et al (2006) Cognitive-behavioural therapy for severe and recurrent bipolar disorder. Randomised controlled trial? Br J Psychiatry 188: 313–320

    Article  PubMed  Google Scholar 

  • Sigmon SC, Stitzer ML (2005) Use of low-cost incentive intervention to improve counselling attendance among methadone-maintained patients. J Subst Abuse Treat 29: 253–258

    Article  PubMed  Google Scholar 

  • Simoens S et al (2006) Pharmaco-economics of community maintenance for opiate dependence: A review of evidence and methodology. Drug Alcohol Depend (Im Druck)

    Google Scholar 

  • Simon GE et al (2006a) Long-term effectiveress and cost of a systematic care program for bipolar disorder. Arch Gen Psychiatry 63: 500–508

    Article  PubMed  Google Scholar 

  • Simon GE et al (2006b) Suicides risk during antidepressant treatment. Am J Psychiatry 163: 41–47

    Article  PubMed  Google Scholar 

  • Statistisches Bundesamt (2004) Krankheitskosten 2002, Wiesbaden

    Google Scholar 

  • Statistisches Bundesamt (2006) Gesundheit, Ausgaben, Krankheitskosten und Personal 2004, Wiesbaden

    Google Scholar 

  • UKATT Research Team (2005) Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ 331: 544–548

    Article  Google Scholar 

  • Wancata J et al (2003) Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry 18: 306–313

    Article  PubMed  Google Scholar 

  • Zarkin GA et al (2005) Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ 14: 1133–1150

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Aloys Prinz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max-Planck-Institut für Psychiatrie, Kraepelinstraße 2-10, 80804, München

    Florian Holsboer

  2. Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule Aachen, Pauwelsstraße 30, 52074, Aachen

    Gerhard Gründer

  3. Ehemals: Psychiatrische Klinik und Poliklinik der Johannes-Gutenberg-Universität Mainz, Untere Zahlbacher Straße 8, 55131, Mainz

    Otto Benkert

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Prinz, A. (2008). Psychopharmakoökonomie. In: Holsboer, F., Gründer, G., Benkert, O. (eds) Handbuch der Psychopharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68748-1_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68748-1_26

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20475-6

  • Online ISBN: 978-3-540-68748-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation